Iruplinalkib Tablets 伊鲁阿克片

Iruak tablets (trade name: Qixinke) are indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK).
Iruak is an ALK inhibitor that can inhibit the phosphorylation of ALK and ROS1 kinases and block the activation of downstream signaling pathway proteins such as ERK, STAT5 and AKT, thereby inducing tumor cell death (apoptosis). The launch of this drug provides a new treatment option for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). [4]
This product is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK). [